Impact of Anti-Sars-Cov-2 Monoclonal Antibodies in the Management of Patients with Lymphoma and COVID19: A Retrospective Study

Blood · 2022 · PMC9665302

Europe PMC

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Among patients who received 3 doses of vaccine, the employment of Anti-S MoAbs showed a trend of superior survival versus those who did not receive Anti-S MoAbs (OS rates 97.3% vs 84.2%, p 0.064).

also in 53,322 other papers

a decreasing trendno p-value reported

Overall, mortality rate was 13.1%, with a decreasing trend between first waves to the last wave of pandemic (18.5% vs 9.4%, p 0.076).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.